References
- Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma – are we there yet? Neuro Oncol 2013;15(1):4-27
- Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62
- Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28):4733-40
- Taal W, Oosterkamp HM, Walenkamp AME, et al. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: the Dutch BELOB study. J Clin Oncol 2013;31(15S):2001
- Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013;31(26):3212-18
- Chinot O, Cloughesy T, Henriksson R, et al. Efficacy and safety of bevacizumab (Bv) plus standard combination temozolomide (T) and radioterapy (RT) in newly diagnosed glioblastoma: final results froma AVAglio. Eur J Cancer 2013;49(suppl 2):S774-5
- Gilbert MR, Dignam J, Won M, et al. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol 2013;31(18S):1
- Cao L, Jiao X, Zuzga DS, et al. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat Genet 2004;36(8):827-35
- Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009;72(14):1217-22
- Herrlinger U, Schafer N, Steinbach JP, et al. Bevacizumab, irinotecan and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT – non methylated glioblastoma patients: updated results from the randomized multicenter GLARIUS Trial. Eur J Cancer 2013;49(suppl 2):S774
- Stupp R, Hegi ME, Gorlia T, et al. Standard chemoradiotherapy ± cilengitide in newly diagnosed glioblastoma (GBM): updated results and subgroup analyses of the international randomized phase III CENTRIC Trial (EORTC trial 26071-22072/Canadian Brain tumor Consortium). Eur J Cancer 2013;49(suppl 2):S775